Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection

Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han and Seung Up Kim

PLOS ONE, 2019, vol. 14, issue 4, 1-14

Abstract: Background/Aims: It is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC). We investigated the predictors of poor treatment outcomes in patients with recurrent HCC treated who were treated with TACE after curative resection. Methods: 428 patients with recurrent HCC after curative resection who were treated with TACE were enrolled. Results: The median age of the study population was 59.2 years. On multivariate analysis, ≥2 TACE procedures within 6 months (hazard ratio [HR] = 1.898), and the des-gamma carboxyprothrombin level (HR = 1.000) independently predicted the progression to Barcelona Clinic Liver Cancer (BCLC) stage C in patients with BCLC stage 0-B HCC (both P

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214613 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 14613&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0214613

DOI: 10.1371/journal.pone.0214613

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().